Imricor Expands U.S. Presence with Second NorthStar Customer
Imricor Medical Systems Inc. (ASX: IMR) is gaining commercial traction in the United States after Children’s Medical Center Dallas selected its NorthStar iMR mapping and guidance system. The hospital becomes Imricor’s second U.S. commercial customer, shortly after the company commenced its American commercial operations.
A key advantage is that Children’s Medical Center Dallas already has an operational Philips iMR laboratory, removing the need for additional lab construction and potentially accelerating the start of procedures. The hospital intends to use NorthStar for cardiac catheterisation procedures involving children with congenital heart conditions while eliminating exposure to ionising radiation.
The agreement also demonstrates NorthStar’s compatibility across major MRI platforms, with Imricor’s initial U.S. customers operating Siemens and Philips systems. Commercial momentum could strengthen further, as several additional children’s and adult hospitals are progressing through the final stages of purchasing discussions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Imricor Expands U.S. Presence with Second NorthStar Customer
Imricor Medical Systems Inc. (ASX: IMR) is gaining commercial traction in the United States after Children’s Medical Center Dallas selected its NorthStar iMR mapping and guidance system. The hospital becomes Imricor’s second U.S. commercial customer, shortly after the company commenced its American commercial operations.
A key advantage is that Children’s Medical Center Dallas already has an operational Philips iMR laboratory, removing the need for additional lab construction and potentially accelerating the start of procedures. The hospital intends to use NorthStar for cardiac catheterisation procedures involving children with congenital heart conditions while eliminating exposure to ionising radiation.
The agreement also demonstrates NorthStar’s compatibility across major MRI platforms, with Imricor’s initial U.S. customers operating Siemens and Philips systems. Commercial momentum could strengthen further, as several additional children’s and adult hospitals are progressing through the final stages of purchasing discussions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au